Optiray (Ioversol)

Optiray is a non‑ionic iodinated contrast agent used in imaging procedures that require vascular or organ enhancement.

• Computed tomography (CT) of the head, chest, abdomen and pelvis: improves delineation of anatomical detail and pathology.
• Angiography: provides clear visualization of blood vessels for diagnostic and interventional procedures.
• Myelography: enhances the spinal canal and nerve root sleeves for better assessment of spinal pathology.
• Urography: highlights the urinary collecting system to aid detection of stones, tumors and obstruction.
• Cardiac CT: assists  with  coronary artery assessment  and  cardiac chamber evaluation.
• Peripheral vascular imaging: supports evaluation  of  peripheral arteries  and  veins.

• Ioversol is an iodine‑based, water‑soluble compound that distributes rapidly in the extracellular fluid after intravenous injection. The high atomic number of iodine absorbs X‑ray photons, increasing radiodensity of blood vessels and perfused tissues, which creates contrast between structures on radiographic images.

Adverse reactions to Optiray may range from mild to severe and should be monitored during and after administration.

Common Side Effects

• Warm sensation or flushing: transient feeling of heat on the skin.
• Nausea or vomiting: mild gastrointestinal upset.
• Metallic taste: brief metallic sensation in the mouth.
• Headache: mild to moderate headache.
• Injection site discomfort: mild pain or irritation at the IV site.

Serious or Rare Side Effects

• Hypersensitivity reactions: urticaria, bronchospasm, or anaphylaxis.
• Renal impairment: acute kidney injury, especially in patients with pre‑existing renal disease.
• Cardiovascular events: hypotension, arrhythmias, or cardiac arrest.
• Seizures: rare neurologic events.
• Pulmonary edema: fluid accumulation in the lungs.
• Death: fatal outcomes in extreme cases of severe reaction.

Before using Optiray, clinicians should assess patient history and monitor for potential adverse events.

• Renal function assessment: evaluate baseline creatinine and eGFR before administration.
• Allergy history: verify any prior reactions to iodinated contrast media.
• Hydration status: ensure adequate patient hydration to reduce renal risk.
• Concomitant nephrotoxic drugs: avoid or adjust dosing of drugs that may worsen kidney function.
• Thyroid disease: use caution in patients with hyperthyroidism or thyroid nodules.
• Store at ambient temperature: keep in original packaging, protect from light and moisture.

Optiray may interact with other medications, altering safety or efficacy.

Major Interactions (Avoid)

• Metformin: increased risk of lactic  lactate  accumulation  due to renal impairment.
• High‑dose  iodine supplements  or potassium iodide  :  excess  iodine  load  may  potent  contrast  effects  and  thyroid  disruption  .

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate volume depletion and renal injury.
• ACE inhibitors/ARBs: can increase risk of contrast‑induced nephropathy.
• Non‑steroidal anti‑inflamatory  NNSA  NSA   NSA  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …